SHINE Technologies announced today it is opening the largest facility in North America dedicated to producing a medical isotope used in targeted cancer therapies.

According to a release, the facility, located in Janesville, Wis., will produce non-carrier-added lutetium-177 (Lu-177) and is currently having equipment installed. After licensing and validation, the company expects to have Lu-177 available for commercial use in late 2023.

“At SHINE, we innovate to serve markets where there is a nexus of unmet demand, challenges where our unique capabilities will drive value, and positive impact on the world,” SHINE CEO Greg Piefer said in a statement. “We’re excited to play an important role in making sure these groundbreaking therapies reach patients faster, potentially saving or extending the lives of many tens of thousands of people each year.”

The biotech company broke ground at the Janesville facility in December 2020.